Neuroscience INSIGHTS


Tauopathy Alzheimer's Disease Models Yield Contrasting Results

In a recent Alzheimer's Research and Therapy article, scientists described failing to elicit beneficial effects from a tau-directed antibody therapy while evaluating its efficacy in the Tg4510 mouse, an Alzheimer's disease (AD) model with a tamoxifen-controlled transgene expressing P301L mutant tau. The results contrast prior successes reported with the antibody therapy the researchers were testing. The therapeutic, a tau oligomer-specific monoclonal antibody (TOMA), was reported to rescue...

Read More

National Drug and Alcohol Facts Week

During the third week of January The National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) host an annual event focusing on substance abuse and its impact on teenagers. Launched in 2010, the National Drug Alcohol Facts Week (NDAFW) focuses on substance abuse education, linking students with scientists and other experts to counteract the myths about drugs and alcohol. NDAFW is...

Read More

A Redox Link between APOE4 and Alzheimer's Disease Risk?

A Redox Link between APOE4 and Alzheimer's Disease Risk? Individuals homozygous for APOE4, one of three common genetic variants encoding Apolipoprotein E (apoE), carry approximately twelve-times higher risk for an Alzheimer's disease (AD) diagnosis. A recent study suggests a potentially critical link between apoE4 and the antioxidant enzyme Thioredoxin-1 (Trx1) may underlie enhanced AD risk in APOE4 carriers. APOE Alleles Modify Alzheimer's Risk ApoE protein is predominantly...

Read More

Chronic Pain Management Research and the Opioid Crisis

Developing novel drugs for chronic pain management — both more effective and less addictive than opioids — will reduce the number of patients at risk of opioid dependence. Chronic Pain and the Opioid Crisis More than 25% of Americans suffer from chronic pain. This is on par with adults from equivalent regions; between 10-25% of adults in other western countries experience chronic pain, while some estimates of...

Read More

Alzheimer's Requires Aggressive Funding — and Better Models

More than 5.5 million Americans are living with Alzheimer's disease (AD), the sixth leading cause of death among adults in the US. Aggressive research funding and improved animal models of Alzheimer's disease are urgent priorities. Increasing Alzheimer's Research Funding On July 19, 2017, the House Appropriations Committee approved an additional $400 million for Alzheimer's disease research in the fiscal year 2018 budget. $400 million was also approved...

Read More

Parkinson's Disease Model with Endogenous LRRK2 Regulation

No single Parkinson's Disease (PD) model fully reproduces the complexity of the disease in humans. Developing an assortment of PD models has been essential for furthering our understanding of, and the development of potential treatments for, the disease. Adding to the arsenal of PD rodent models, in conjunction with The Michael J. Fox Foundation (MJFF) for Parkinson's Research, a mouse model carrying targeted replacement human LRRK2 G2019S...

Read More

Animal Models of Addiction and the Opioid Crisis

As the opioid crisis continues, every week brings new and alarming developments, legislative attempts to address the epidemic, and new formulations of street drugs which are contaminated, or resistant to naloxone. This has sparked a variety of debates concerning how we can best address the situation. From a public health perspective, however, the need to explore relevant and predictive animal models of addiction and develop novel strategies...

Read More

Accelerating Parkinson's Disease Research Through Strategic Partnerships

The Michael J. Fox Foundation (MJFF), established in 2000, is dedicated to finding a cure for Parkinson's disease (PD) by supporting research agendas toward development of improved therapies for Parkinson's disease patients. Unlike many private research funding institutions that rely on external scientific advisors and boards for how to allocate donor-raised research dollars, the MJFF has an in-house team of trained scientists and project managers that oversee...

Read More

Rodent Alzheimer's Disease Model Supports New Therapies

In late 2016 Biogen reported exciting results for aducanumab, their Phase 1 monoclonal antibody therapy for Alzheimer's disease (AD). Patients who received aducanumab showed significant and dose-dependent reduction of brain Amyloid-β (Aβ) and slowing of disease progression. Pre-clinical studies in the APPSWE/Tg2576 mouse model of AD provided the mechanistic clues, dosing insights, and efficacy data that informed the design of Biogen's successful aducanumab Phase I trial. Now,...

Read More

CNV Psychiatric Disease Models Q&A

Dr. Michael Didriksen, whose work with Lundbeck Pharmaceuticals is bridging preclinical and clinical schizophrenia and psychosis science, presented a webinar focused on the application of three novel psychiatric disease models, all carrying high-risk genetic copy number variations (CNVs). His presentation on the research applications of mice carrying high-risk CNVs generated substantial interest from the neuropsychiatric community. Here are some of the most popular questions we received from...

Read More